Navigation Links
Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
Date:9/13/2011

EAST BRUNSWICK, N.J., Sept. 13, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that John H. Johnson, Chief Executive Officer and President of Savient will present at the Sixth Annual JMP Securities Healthcare Conference on Wednesday, September 28, 2011 at 9:30 a.m. Eastern Time.  The conference will be held at the St. Regis hotel in New York City.

A live webcast of the presentation can be accessed through the investor relations section of the Company's website at www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy.  Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA.  MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S.  For more information, please visit the Company's website at www.savient.com.

SVNT - GContact:Mary Coleman

Carney Noensie Savient Pharmaceuticals, Inc.

Burns McClellaninformation@savient.com

cnoensie@burnsmc.com (732) 418-9300

(212) 213-0006
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
2. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
3. Savient Pharmaceuticals to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
4. Savient Pharmaceuticals Reports Second Quarter 2011 Financial Results
5. Savient Pharmaceuticals to Hold Second Quarter 2011 Financial Results Conference Call on Thursday, August 4, 2011
6. Savient Pharmaceuticals Marketing Authorization Application for KRYSTEXXA® Accepted for Review by European Medicines Agency
7. Savient Pharmaceuticals Reports First Quarter 2011 Financial Results
8. Savient Pharmaceuticals Submits European Marketing Authorization Application for KRYSTEXXA®
9. Savient Pharmaceuticals Names Seasoned Pharma Exec Richard Crowley EVP Biopharmaceutical Operations
10. Savient Pharmaceuticals to Present Multiple Abstracts at The European League Against Rheumatism (EULAR) 2011 Annual Congress
11. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA:CTIC) today announced ... Food and Drug Administration (FDA) on February 4, 2016, ... on the clinical studies being conducted under the Company,s ... hold impacts part of the clinical work currently being ... clinical trials. --> ...
(Date:2/5/2016)... 2016  Despite the recent explosion in Big Data, ... to embrace Big Data due to the inherent costs ... side, organizations have begun looking to Big Data as ... adherence. --> --> ... LLC, Big Data has started informing many decisions. In ...
(Date:2/5/2016)... -- Redwood Scientific Technologies, Inc. announced today the development and ... balance their hormones. This product will be featuring Redwood,s ... Cardiff , President and CEO. "I am proud that ... of women across the country and around the world ... research and development team is confident that through the ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... If you are feeling that your ... are not alone. According to the Center for Disease Control and Prevention (CDC), 34.9% ... diabetes and certain types of cancer, some of the leading causes of preventable death. ...
(Date:2/8/2016)... ... February 08, 2016 , ... Steve Helwig & Associates Insurance & ... community enrichment program, has teamed up with Citizens Opposed to Domestic Abuse in support ... abuse. To support all those victimized by the fear of violence in their own ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... serving the greater Venice, FL area, has initiated a fundraiser for a two ... accident just four days after Christmas. To support this beautiful child who is ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... firm, announced today that nominations will be accepted February 8, 2016 through ... , Awards include the Information Security Executive® of the Year, which ...
(Date:2/8/2016)... ... February 08, 2016 , ... Eating disorders and post-traumatic stress ... women and men with eating disorders report a history of trauma, research suggests ... of an eating disorder. , At the 2016 iaedp Symposium, the workshop, ...
Breaking Medicine News(10 mins):